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INTRODUCTION
Methotrexate (MTX) is a folic acid antagonist that in-
hibits cell division by interfering with DNA synthesis 
and cell replication (1). It has been used for more than 
50 years as a chemotherapy agent and immune system 
suppressant in the treatment of various medical condi-
tions, primarily tumors and autoimmune diseases. In 
gynecology, MTX has found its use in the treatment of 
two disorders, ectopic pregnancy and gestational trop-
hoblastic neoplasia (GTN). 
An ectopic pregnancy mostly occurring in the fallopian 
tube can also be cervical, ovarian, abdominal, intersti-
tial (cornual) or located in a previous cesarean section 
scar. h e incidence of ectopic pregnancy is increasing 
worldwide (mainly due to the increased incidence of 
pelvic inl ammatory disease and assisted reproducti-
on technologies) and is reported to be between 0.5% 
and 2% (11.5 per 1000 pregnancies) (2, 3). Optimal 
candidates for MTX treatment of ectopic pregnancy 
are hemodynamically stable patients, willing and able 
to comply with post-treatment follow-up, having a 
human chorionic gonadotropin (hCG) serum value 
≤5000 mIU/mL and no fetal cardiac activity in ecto-
pic gestational sac (4). h e size of ectopic mass being 
less than 3 to 4 cm is also commonly used as a patient 
selection criterion; however, this has not been entirely 
coni rmed as a predictor of successful treatment. Two 
most commonly used protocols for MTX administra-
tion are single and multiple dose ones (four MTX do-
ses which alternate with leucovorin). In 15% of cases, 
surgery is required due to treatment failure (3).
Gestational trophoblastic neoplasia (GTN) is a term 
used for malignant forms of gestational trophoblastic 
disease and includes the following conditions: invasive 
mole, choriocarcinoma, placental site trophoblastic tu-
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mor and epithelioid trophoblastic tumor. h ese tumors 
develop following some form of pregnancy, half of them 
at er hydatidiform mole, one-forth develop at er mis-
carriage or tubal pregnancy and the remaining fourth 
develop at er normal pregnancy and are usually dia-
gnosed by persistently elevated serum human chorionic 
gonadotropin (hCG) levels (5). h e i rst report of MTX 
therapy of GTN appeared in 1956 (6) and today it has 
become the i rst choice of treatment for low-risk GTN. 
GTN is staged clinically and classii ed into low-risk or 
high-risk disease according to the FIGO/WHO scoring 
system (7). Patients with high-risk disease are primari-
ly treated with combination chemotherapy, EMA-CO 
(etoposide, methotrexate, actinomycin D, cyclophosp-
hamide, vincristine), since single-agent chemotherapy 
has shown low ei  ciency. On the other hand, MTX is the 
i rst choice therapy for low-risk disease, which includes 
non-metastatic neoplasia (except for lung metastasis), 
where the WHO score is 6 or less in FIGO stage I-III. 
h e aim of this study was to present MTX treatment ca-
ses and compare treatment results at our center.
PATIENTS AND METHODS
A retrospective case-series study was conducted using 
data from medical records of patients treated with MTX 
from October 2012 until May 2017 at the Department 
of Gynecology and Obstetrics, Merkur University Hos-
pital, a tertiary referral center in Zagreb, Croatia. Pa-
tients treated with MTX were identii ed in medical re-
cords. During this 4 and a half-year period, 11 women 
were treated with MTX, among which 6 women were 
treated for ectopic pregnancy and 5 for low-risk GTN 
disease. Of the 6 cases of ectopic pregnancy, 5 tubal and 
1 case of cornual pregnancy were diagnosed. General 
data (age, gravidity, parity) were collected with special 
attention to data relevant for determined study out-
comes, i.e. hCG levels, indication for MTX treatment, 
as well as treatment response and outcome for both 
ectopic pregnancy and GTN. Single dose protocol was 
used in all cases treated for ectopic pregnancy (1 mg/
kg MTX intramuscularly (im)) and hCG values were 
checked on days 4-5 and days 7-9. Second dose was 
administered if decrease in hCG levels between these 
two days was less than 15 percent. At er second testing, 
hCG testing was repeated weekly until it became nega-
tive. Patients included in this study with the diagnosis 
of GTN were those with low-risk disease according to 
the FIGO/WHO scoring system and were treated with 
the 8-day single-agent MTX along with leucovorin (fo-
lic acid) rescue protocol. h e dosage was 50 mg/day im 
on days 1, 3, 5 and 7 with leucovorin 15 mg im 24 hours 
at er each dose of MTX on days 2, 4, 6 and 8. From that 
time, hCG levels were measured weekly and, in case of 
persistently elevated hCG levels, an additional 8-day 
single agent MTX protocol was repeated. If at er two 
cycles no symptom improvement was observed and/or 
hCG values were rising, further management was dis-
cussed with patients and either another course of single 
agent treatment or treatment with EMA/CO protocol 
(etoposide, methotrexate, actinomycin D, cyclophosp-
hamide, vincristine) was applied. h e study had recei-
ved approval of the departmental clinical board. Since 
personal data of patients were not used, the patient in-
formed consent was not required.
RESULTS
During the study period, 11 women were treated with 
MTX. Data on 6 patients with ectopic pregnancy, i.e. 
age, gravidity, parity, hCG levels before and at er MTX 
administration, as well as treatment outcomes are 
shown in Table 1. Among 5 tubal pregnancies, single 
dose MTX protocol was successful in 4 (80%) cases, 
with 1 case treated surgically due to failure of MTX 
therapy (patient No. 5). In this case, at er initial tre-
atment with single dose MTX, hCG levels rose on day 
4 without expected decline of hCG levels on day 7. h e 
patient was reluctant to receive a repeated course of 
MTX. hCG values continued to rise on day 10, and 
ultrasound examination on day 11 revealed free l uid 
in Douglas cavity suggestive of abdominal bleeding. A 
decision was made to perform laparoscopic unilateral 
salpingectomy. h e diagnosis of ectopic pregnancy 
was coni rmed by histopathology. h e study included 
1 case of cornual pregnancy treated by MTX (patient 
No. 6). h e diagnosis was made on ultrasound exa-
mination showing a gestational sac separate from the 
uterine cavity and myometrial thickness of less than 5 
mm, along with a hCG value of 953 IU/L. Seven days 
at er administration of the i rst single dose of MTX, 
the patient developed abdominal pain and signs sug-
gestive of abdominal bleeding. Rupture of cornual pre-
gnancy was found during surgery. 
Table 1.
Data and treatment outcomes in patients with ectopic 





















1 43 G2P1 757 / 920 441 184 37
2 29 G4P1 263 / / 36 / /
3 26 G2P0 252 245 / 122 31 /
4 37 G2P0 519 749 563 220 30 8
5 40 G2P0 1031 1873 1638 LPSC
6* 27 G2P1 953 LAP
hCG = human chorionic gonadotropin (IU/L); G = gravidity; P = 
parity; LPSC = laparoscopy; LAP= laparotomy; 6* = case of cornual 
pregnancy
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Table 2. 
Data and treatment outcomes in patients with gestational trophoblastic neoplasia: age, gravidity, parity, and hCG levels
















7 17 G1P0 >225000 115981 107112 76262 36853 3921 754
Recovery without any further 
interventions
8 46 G3P1 >709000 36738 36738 31113 5852 6872 9400
EMA-CO after 2 courses of 
MTX treatment
9 49 G11P5 >373000 50771 6030 1306 390 292 316
Abdominal hysterectomy and 
bilateral adnexectomy, nega-
tivization of hCG
10 49 G7P3 >74000 7203 7203 / / 4110 5869
EMA-CO after 2 courses of 
MTX treatment and surgery 
(abdominal hysterectomy and 
bilateral adnexectomy)
11 25 G2P1 >94000 5420 5420 / 4521 / 1988
Further chemotherapy with 
EMA-CO required
G = gravidity; P = parity; D&C = dilatation and curettage; hCG = human chorionic gonadotropin; *hCG initial represents the i rst hCG value 
upon which gestational trophoblastic disease (neoplasia) was suspected, hCG max at er D&C refers to the maximal hCG value measured du-
ring the period between the i rst dilatation and curettage performed and administration of MTX therapy, while hCG before MTX represents 
the i nal value before administration of MTX therapy: **hCG MTX + week refers to the period of hCG measurement at er MTX treatment
In total 5 cases of GTN were treated with MTX. 
Among them, 3 developed from partial hydatidiform 
mole (patients Nos. 7, 10 and 11), while the remai-
ning 2 developed from complete hydatidiform mole 
(patients Nos. 8 and 9). All 5 cases were low-risk di-
seases according to the FIGO/WHO scoring system. 
Data on patients with GTN, i.e. age, gravidity, parity, 
hCG levels (initial, at er dilatation and curettage, and 
then weekly), as well as treatment outcomes are shown 
in Table 2. Patients Nos. 7, 8, 10 and 11 had invasive 
mole. Patient No. 7 recovered at er the i rst course of 
single agent multiple MTX treatment and was alive 
and well during the follow-up. Patient No. 11 had no 
follow-up at er the i rst week of single agent multiple 
MTX treatment. h e patient attended follow-up at er 4 
weeks without satisfactory decrease of hCG values and 
was of ered further treatment with EMA/CO protocol. 
Similarly, patients Nos. 8 and 10 had good initial res-
ponse but at er 4 weeks and a repeated course of single 
agent multiple MTX treatment had a rise of hCG va-
lues and were also treated by EMA-CO protocol. All 
these 3 patients (Nos. 8, 10 and 11) attended follow-up 
at 4-6 months at er completed treatment and were ali-
ve and well with negative values of hCG. Patient No. 9 
had choriocarcinoma. h ere were no signs of metasta-
ses and she was also listed as low-risk. However, at er 
initial treatment with good response and decline of 
hCG values, continuously elevated hCG values despite 
repeated single agent multiple MTX treatment were 
observed. Considering this, in combination with per-
sistent vaginal bleeding, age of 49 years, ovarian theca 
lutein cysts and pelvic pressure, a decision was made 
to perform hysterectomy and bilateral salpingoopho-
rectomy on the patient’s request. h e patient recovered 
well and hCG values were slightly elevated at er one 
and two weeks following surgery but became negative 
a week later and remained negative during follow-up. 
DISCUSSION
During the study period, there were 99 cases of ectopic 
pregnancy at our department and only 6 of them were 
treated by MTX, yielding an incidence of 6% of ecto-
pic pregnancies treated by MTX. h e success rate for 
treatment of tubal ectopic pregnancies with MTX was 
80%, while the single case of cornual pregnancy was 
not successfully treated with MTX. According to the 
available literature, the success rate of MTX treatment 
ranges between 63% and 97%. Such a dif erence is 
due to the heterogeneity of patient groups, dif erent 
inclusion criteria used and dif erences in MTX tre-
atment protocols. In a randomized trial by Song et al., 
the success rate of the single-dose protocol was 83% 
(8). Lipscomb et al. report an even higher success rate 
of 90.7% (9), whereas a tertiary center from Turkey 
reports a success rate of 93.0% (10). h e single best 
prognostic indicator of successful MTX treatment is 
initial serum hCG level (11). In a study by Menon et 
al., the reported failure rates were 1.5% if initial hCG 
level was <1000 mIU/mL and 5.6% if initial hCG le-
vels were between 1000 and 2000 mIU/mL (12). h is 
is in concordance with our results where all cases with 
initial hCG level below 1000 IU/L responded well to 
treatment. Only one case had initial hCG level abo-
ve 1000 IU/L and was ultimately treated surgically. In 
our case series, the single dose protocol was applied in 
all cases (1 mg/kg/day im). Another treatment opti-
on is 50 mg of MTX per square meter of body surface 
area (BSA). h e hCG concentration usually declines 
to less than 15 mIU/mL by day 35 post injection (13). 
If the hCG does not decline to zero, a new pregnan-
cy should be excluded; if hCG is rising, transvaginal 
ultrasound should be performed in order to exclude 
persistent disease with possible complications. In case 
No. 5, ultrasound examination was performed at er an 
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increase in hCG level had been observed, and revea-
led a persistent ectopic gestational sac with free l uid 
in Douglas cavity. Surgical treatment was performed. 
Our study included 1 case of cornual pregnancy trea-
ted with MTX. According to RCOG Green-top Gui-
delines, excision of rudimentary horn where cornual 
pregnancy is present seems to be the best approach in 
the treatment of cornual pregnancy (4). However, a 
recently published case study describes successful tre-
atment of cornual pregnancy with multi-dose protocol 
of MTX and folic acid (14). In our case, we attempted 
medical treatment of cornual ectopic pregnancy since 
hCG values were low and the patient had no clinical 
symptoms. Unfortunately, hCG values were not chec-
ked on day 4, and on day 7 prior to hCG testing the 
patient had rupture of cornual ectopic pregnancy. 
Low-risk GTN is another indication for MTX tre-
atment. Treatment protocols vary among medical cen-
ters worldwide and several drug schedules exist. h ree 
most ot en used options are as follows: MTX 0.4 mg/
kg intramuscularly (im) for 5 days, repeated every 2 
weeks. h is protocol has a primary failure rate of 11%-
15% for non metastatic disease and 27%-33% for me-
tastatic disease (15); MTX 50 mg im or 1 mg/kg every 
other day for 4 doses with leucovorin 15 mg or 0.1 
mg/kg 24-30 hours at er each dose of MTX is a widely 
used protocol but has a 20%-25% primary failure rate 
(16); and MTX 50 mg/m2 BSA im given weekly is the 
least successful regimen with a 30% primary failure 
rate (17). h ere were 5 cases of GTN during the study 
period, all of them being coni rmed by histopathology. 
All patients included in our study had low-risk GTN 
disease and were treated with the 8-day single-agent 
MTX with folic acid leucovorin rescue protocol. h e 
overall success rate of the initial MTX treatment was 
only 20%, however, the numbers are small. h ree of 
5 (60%) cases required further multiple agent chemo-
therapy by EMA-CO (etoposide, methotrexate, acti-
nomycin D, cyclophosphamide, vincristine). In one 
case, despite multiple MTX treatments, the patient still
had signs of trophoblastic activity. Considering her 
age, symptoms and request for dei nitive treatment, 
hysterectomy was performed. h e EMA-CO protocol 
is a highly ef ective second line treatment for high-risk
GTN. In a study by Turan et al., 33 patients with 
high-risk GTN were treated, 23 of them primarily 
with EMA-CO and 10 secondarily with EMA-CO af-
ter failure of single agent or MAC (methotrexate, acti-
nomycin D, cyclophosphamide, or clorambucile) tre-
atment. Survival rate was 91.3% (21/23) for primary 
treatment and 90% (9/10) for secondary treatment 
(18). In our case series, 3 patients received EMA-CO 
protocol and on follow-up all were alive and well. Suc-
cess rate in our case series was lower than in previo-
usly published studies, where the overall success rate 
of treatment of low-risk GTN disease with MTX was 
74% in a study performed in Turkey (19) and 83% in 
a study from Saudi Arabia (20). In a study conducted 
by Sita-Lumsden et al., the success rate of single-dose 
MTX treatment ranged from 75% for FIGO score 0-1 
through to 31% for those with FIGO score 6 (21). h e 
low success rate in our study may have been due to 
erroneous classii cation of GTN disease, however, to 
the best of our knowledge, all patients met the criteria 
for low-risk group and therefore had an indication for 
treatment with the single agent MTX 8-day protocol. 
h e diagnosis was based on high trophoblastic activity 
at er evacuation of the uterus for hydatidiform mole 
and signs of invasive trophoblastic activity on ultraso-
und and color Doppler examination, which has been 
proven as a useful supplementary tool in the diagnosis 
and management of GTN (22, 23). Choriocarcinoma 
is more likely to develop at er complete hydatidiform 
mole and it was the case in patient No 9. 
Limitations of this study include small sample size 
consisting of only 6 cases of ectopic pregnancies and 
5 cases of low-risk GTN disease eligible for MTX tre-
atment. Furthermore, even though all low-risk GTN 
cases were managed and treated according to the same 
protocol, a single unii ed protocol for this condition 
does not exist at our department, which is essential 
when dealing with such serious and distinctive me-
dical conditions. Also, some cases lacked appropria-
te follow-up (patients Nos. 6 and 10), which might 
have had an impact on further management of these 
patients. All of this will be addressed in future mana-
gement of gestational trophoblastic disease and hope-
fully yield improved success rates of treatment with 
MTX, especially concerning GTN.
CONCLUSION
h e results of this study coni rmed the usefulness of 
MTX in the treatment of ectopic pregnancies, particu-
larly when eligible cases are attentively and appropria-
tely selected according to available medical informa-
tion. A success rate of 80% for the treatment of tubal 
ectopic pregnancies proves MTX to be a potent drug 
for the treatment of this condition. Ef orts should be 
made to raise awareness among women af ected with 
these conditions and among medical practitioners in-
volved in their treatment regarding the usefulness and 
advantages of MTX treatment of ectopic pregnancies. 
h e usefulness of MTX treatment for low-risk GTN 
disease was not coni rmed in this study. With a success 
rate of only 20% (other cases requiring further com-
bination chemotherapy or surgery), we were unable 
to coni rm at our department the ei  ciency of MTX 
treatment of low-risk GTN disease as suggested by the 
FIGO Committee on Gynecologic Oncology (24). Ad-
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ditional research, as well as follow-up of a larger num-
ber of our patients is needed to investigate the reasons 
of this low success rate.
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Cilj: Cilj rada je prikazati rezultate liječenja metotreksatom dviju ginekoloških bolesti u tercijarnom referentnom centru. 
Metode: Provedena je retrospektivna studija uporabom podataka iz povijesti bolesti pacijentica liječenih metotreksatom 
tijekom četverogodišnjeg razdoblja u Kliničkoj bolnici Merkur, Zagreb, Hrvatska. U studiju je uključeno 11 pacijentica koje 
su podijeljene u 2 skupine: 6 pacijentica s ektopičnom trudnoćom (5 tubarnih i 1 kornualna) i 5 pacijentica s gestacijskom 
trofoblastičnom neoplazijom (GTN) niskog rizika. Pacijentice s ektopičnom trudnoćom liječene su jednokratnom dozom 
metotreksata (1 mg/kg/dan intramuskularno), dok su pacijentice s GTN niskog rizika liječene osmodnevnim protokolom 
metotreksatom i leukovorinom. Rezultati: Od 5 pacijentica s tubarnom trudnoćom liječenje metotreksatom bilo je uspješno 
u 4 (80%) slučaja, dok je u 1 slučaju bilo potrebno kirurško liječenje. U 1 zabilježenom slučaju kornualne trudnoće liječenje 
metotreksatom bilo je neuspješno te je pacijentica zbrinuta kirurški. Od 5 slučajeva GTN liječenih metotreksatom u 3 sluča-
ja bio je potreban nastavak kemoterapije po EMA-CO protokolu, dok je u 1 slučaju bilo potrebno dodatno kirurško liječenje 
te je ukupna uspješnost liječenja metotreksatom iznosila 20 %. Zaključak: Metotreksat se može smatrati učinkovitom 
terapijom u liječenju pažljivo odabranih pacijentica s ektopičnom trudnoćom, dok njegova uspješnost u kemoterapijskom 
liječenju GTN niskog rizika nije potvrđena.
Ključne riječi: metotreksat, ektopična trudnoća, gestacijska trofoblastična bolest, gestacijska trofoblastična neoplazija,  
 invazivna mola, koriokarcinom
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